Jun 24, 2025 7:00 am EDT iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results
Jun 23, 2025 4:15 pm EDT iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call
Jun 16, 2025 7:00 am EDT iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment
May 5, 2025 8:00 am EDT iBio’s First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model
Apr 22, 2025 8:00 am EDT iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio
Apr 7, 2025 7:00 am EDT iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline